Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of capecitabine and aflibercept in metastatic colorectal cancer unsuitable for doublet/triplet chemotherapy
2013-002308-15Phase 2Unknown
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Oct 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and aflibercept in colorectal cancer (CRC), sponsored by Guy's and St Thomas' NHS Foundation Trust. Primary endpoint: Safety and tolerability (phase I). Status: unknown.
02
Drugs
capecitabineaflibercept
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2013-002308-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002308-15.